Severine R. Vermeire

Severine R. Vermeire

Leuven, VLG 3000, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 825 publications

High relapse rates after budesonide in microscopic colitis: a large retrospective analysis revealing the need for advanced therapies.

High relapse rates after budesonide in microscopic colitis: a large retrospective analysis revealing the need for advanced therapies.

Journal: Acta gastro-enterologica Belgica

Published: July 08, 2026

Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease: a single-center retrospective case series.

Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease: a single-center retrospective case series.

Journal: Acta gastro-enterologica Belgica

Published: July 08, 2026

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

Journal: medRxiv : the preprint server for health sciences

Published: May 25, 2026

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Journal: Journal of Crohn's & colitis

Published: March 24, 2026

Estimated benefits and willingness of remote monitoring in IBD patients in remission under maintenance therapy: results of a questionnaire in a tertiary referral centre.

Estimated benefits and willingness of remote monitoring in IBD patients in remission under maintenance therapy: results of a questionnaire in a tertiary referral centre.

Journal: Acta gastro-enterologica Belgica

Published: February 26, 2026

Patient Preferences for Inflammatory Bowel Disease Treatment: Results from a Global Survey Conducted in Partnership with the European Federation of Crohn's & Ulcerative Colitis Associations.

Patient Preferences for Inflammatory Bowel Disease Treatment: Results from a Global Survey Conducted in Partnership with the European Federation of Crohn's & Ulcerative Colitis Associations.

Journal: The patient

Published: January 26, 2026

Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's Disease.

Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's Disease.

Journal: Clinical pharmacokinetics

Published: January 09, 2026

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 22, 2025

Hidradenitis suppurativa patients exhibit a distinctive and highly individualized skin virome.

Hidradenitis suppurativa patients exhibit a distinctive and highly individualized skin virome.

Journal: mSystems

Published: December 15, 2025

Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.

Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease.

Journal: Journal of Crohn's & colitis

Published: November 20, 2025

Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.

Long-Term Safety of Upadacitinib in Patients With Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 08, 2025

Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.

Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.

Journal: Inflammatory bowel diseases

Published: September 24, 2025

Showing 1-12 of 825

Last Updated: 09/26/2026